1. Aprobación de Wegovy Oral y Expansión del Acceso.
La Administración de Alimentos y Medicamentos de EE. UU. (FDA) ha aprobado la versión en píldora del popular medicamento para la pérdida de peso Wegovy, marcando un hito significativo al ser la primera medicación oral diaria para tratar la obesidad. Esta decisión de Novo Nordisk promete ampliar el acceso de los pacientes y transformar el panorama del tratamiento, ofreciendo una alternativa a las inyecciones semanales.
- Us regulators approve wegovy pill, first oral medication to treat obesity food and drug administrations approval hands drugmaker novo nordisk an edge in the race to market an obesity pill us regulators on monday gave the green light to a pill version of the blockbuster weight-loss drug.
- Fda approves wegovy pill for weight loss, the first daily oral medication of its kind regulators at the u.s. Food and drug administration on monday gave the green light to a pill version of the blockbuster weight-loss drug wegovy, the first daily oral medication to treat obesity.
- Fda approves oral wegovy pill for weight loss the u.s. Regulator cleared a pill version of novo nordisks blockbuster wegovy obesity drug, marking the first daily oral alternative to the injectable therapy. The approval could broaden patient access and escalate competition in the glp-1.
2. La Intensa Competencia en el Mercado de Fármacos para la Obesidad.
El mercado de medicamentos para la obesidad se ha vuelto altamente competitivo, con Novo Nordisk y Eli Lilly liderando la carrera. La aprobación de Wegovy oral intensifica esta rivalidad, mientras que Eli Lilly avanza con sus propios fármacos experimentales como Retatrutide y Orforglipron, que muestran resultados prometedores en la pérdida de peso y el alivio del dolor. Las empresas también están explorando estrategias de precios y distribución para ganar cuota de mercado.
- Fda approves first glp-1 pill for obesity from wegovy maker novo nordisk the u.s. Food and drug administration on monday approved the first-ever glp-1 pill for obesity from wegovy maker novo nordiska landmark decision that health experts say could open up treatment access to more patients. Novo.
- Eli lillys experimental pill could help you ditch glp-1 obesity shots, trial finds eli lillys experimental oral drug, orforglipron, has shown promise as a potential alternative for indi.
- Eli lillys amylin drug shows 20 weight loss, enters final trials eli lilly is moving closer to expanding its dominance in the global obesity drug market. The pharmaceutical giant announced on thursday that it will begin late-stage trials of its experimental amylin-based obesity treatment,.
- Novo nordisk stumbles against eli lilly in glp-1 drug battle. Which stock is best? in the battle between weight-loss drug companies, eli lilly has emerged as the clear winner for investors.
3. Acuerdos de Precios y Cobertura de Medicamentos GLP-1.
La administración Trump ha negociado acuerdos históricos con Eli Lilly y Novo Nordisk para reducir los precios de los medicamentos GLP-1 para la pérdida de peso y la diabetes. Estos acuerdos buscan ampliar el acceso a través de Medicare, Medicaid y plataformas directas al consumidor, con el objetivo de hacer que estos tratamientos sean más asequibles para millones de estadounidenses.
- Trump secures major deal to cut weight loss drug prices nationwide president donald trump has reached historic agreements with pharmaceutical leaders eli lilly and novo nordisk to drastically lower the prices of their blockbuster weight loss and diabetes drugs.
- Lilly, novo near white house deal to cut obesity drug prices, gain medicare access eli lilly and novo nordisk are reportedly nearing agreements with the white house to lower prices for their obesity drugs in exchange for medicare access.
- Trump cuts obesity drug prices president trump announced a deal with novo nordisk and eli lilly to cut u.s. Prices of glp-1 weight-loss drugs for medicare, medicaid and cash patients to roughly 149350.
- Trump announces deals with eli lilly, novo nordisk to slash weight loss drug prices, offer some medicare coverage nov 6 2025president donald trump announced deals with eli lilly and novo nordisk to slash the prices of some of their obesity drugs, including .
4. Controversias, Riesgos y Usos Más Allá de la Pérdida de Peso.
A pesar de su eficacia, los medicamentos GLP-1 enfrentan controversias y preocupaciones. Se han reportado efectos secundarios graves, advertencias sobre salud mental y la necesidad de uso a largo plazo para mantener los resultados. Además, su uso indebido para fines cosméticos ha generado escasez para pacientes diabéticos. Sin embargo, la investigación también explora su potencial para tratar otras condiciones como la adicción y enfermedades cardiovasculares, aunque no han mostrado éxito en la desaceleración del Alzheimer.
- Miracle drug or medical gamble? glp-1 weight-loss meds linked to thousands of severe side effects colorado springs, colo. Theyve been billed as miracle drugs, promising weight loss, improved heart health, and better.
- Its interesting they are pushing a drug that has known side effects and appears to be problematic in keeping weight off when discontinued. I thought the goal was a healthy diet?
- Obesity drug semaglutide fails to slow alzheimers drug maker novo nordisk says semaglutide, the active ingredient for the weight loss jab wegovy, does not slow alzheimers - despite initial hopes that it might help against dementia.
- Glp-1s could end up being the first true longevity drug as the world battles a rising obesity crisis todayheadline glp-1s are the hottest drugs on the market. While doctors have prescribed these drugs to treat type-2 diabetes for decades, these treatments broke into the public consciousness when.
- Glp-1s have a surprising new role tackling alcohol and drug addiction. The washington post youve likely heard of glp-1 medications, the groundbreaking drugs transforming the landscape of weight management and diabetes care. But what if these same medications held a key to unlocking another.
- Australias drug regulator issues mental health warning for weight-loss drugs including ozempic health the drug regulator has added two new safety warnings about mental health and contraception for people taking high-profile diabetes and weight-loss drugs.